Get started
Author

Shimrit Ringelstein‐Harlev

Observed names: S. Ringelstein-Harlev, S. Ringelstein‐Harlev, S., Ringelstein-Harlev, Shimrit Ringelstein-Harlev
ORCID: 0000-0003-4897-1466
Observed ORCID: 0000-0003-4897-1466
OpenAlex ID: A5083305301
Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
2019 · Yishai Ofran, Shimrit Ringelstein-Harlev, et al. · Leukemia · 72
Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies
2021 · Ronit Gurion, Uri Rozovski, et al. · Haematologica · 58
PDF
Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation
2019 · Ofrat Beyar-Katz, Noa Lavi, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 14
Chronic lymphocytic leukemia cells acquire regulatory B-cell properties in response to TLR9 and CD40 activation
2018 · Shimrit Ringelstein-Harlev, Irit Avivi, et al. · Cancer Immunology Immunotherapy · 11
Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury
2021 · Razan Sakran, Gai Milo, et al. · Journal of Oncology Pharmacy Practice · 10
ERK Activity in Immature Leukemic Cells Drives Clonal Selection during Induction Therapy for Acute Myeloid Leukemia
2020 · Michal Hayun, Maria Zaatra, et al. · Scientific Reports · 9
PDF
Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
2023 · Israel Henig, Jonathan Isenberg, et al. · Vaccines · 8
PDF
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study
2023 · Ofrat Beyar Katz, Chava Perry, et al. · European Journal Of Haematology · 8
Prognostic Impacts of Age, Diagnosis Time, and Relapses in Primary CNS Lymphoma
2024 · Sona Ohanyan, Chen Buxbaum, et al. · Journal of Clinical Medicine · 6
PDF
Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression
2022 · Tehila Azoulay, Ilana Slouzky, et al. · Cancer Immunology Immunotherapy · 5
Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma
2026 · Marina Gomez-Llobell, Roni Shouval, et al. · Transplantation and Cellular Therapy · 4
Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers
2025 · Giulia Magno, Kai Rejeski, et al. · Blood Advances · 3
PDF
Immune dysfunction complexity in chronic lymphocytic leukemia ‒ an issue to consider when designing novel therapeutic strategies
2020 · Shimrit Ringelstein-Harlev · Leukemia & lymphoma/Leukemia and lymphoma · 3
CCR5 predicts neurotoxicity in CAR ‐T‐cell therapy
2025 · Ayal Rozenberg, Shahar Shelly, et al. · British Journal of Haematology · 2
PDF
CNS Prophylaxis in Diffuse Large B-Cell Lymphoma: A Common Toxic Clinical Practice Based on Abundant Opinion, Despite Evidence Suggesting Futility
2023 · Ofrat Beyar Katz, Shimrit Ringelstein-Harlev, et al. · Blood · 2
PDF
Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
2022 · Irit Avivi, Chava Perry, et al. · Annals of Hematology · 2
Single agent oral selinexor as a key to potential cure in refractory diffuse large B-cell lymphoma: case report and literature review.
2021 · Nurit Horesh, Michal Weiler-Sagie, et al. · PubMed · 2
Minimal Residual Disease Surveillance in Chronic Lymphocytic Leukemia by Fluorescence-Activated Cell Sorting
2014 · Shimrit Ringelstein-Harlev, Riva Fineman · Rambam Maimonides Medical Journal · 2
PDF
High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies
2025 · Yousef Laham, Shimrit Ringelstein-Harlev, et al. · Haematologica · 1
PDF
In patients with follicular lymphoma, delayed-onset neutropenia induced by anti-CD20 monoclonal antibodies frequently occurs during maintenance therapy and is preferentially associated with obinutuzumab
2024 · Nashwa Fadaos, Yossi Ben Dor, et al. · Annals of Hematology · 1
Eosinophilic pleocytosis in the cerebrospinal fluid following CAR-T cell therapy for CNS lymphoma: A case for warning?
2024 · Mayasa Abu Ata, Israel Henig, et al. · Acta Haematologica · 1
Acceleration of non-Hodgkin lymphoma progression during pregnancy in a murine model
2024 · Netanel A. Horowitz, Ali Abed Al Wahad, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 1
The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia
2023 · Baher Krayem, Tsila Zuckerman, et al. · Blood · 1
In chronic lymphocytic leukemia, activation of the thrombopoietin receptor promotes T‐cell inhibitory properties, contributing to immunosuppression
2022 · Shimrit Ringelstein‐Harlev, Mona Fanadka, et al. · European Journal Of Haematology · 1
Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
2022 · Ofrat Beyar-Katz, Chava Perry, et al. · Research Square · 1
PDF
Works count: 42
Citation count: 230
H-index: 8
I10-index: 5
Year
Topic
Type